Research focusing on how to deliver drugs to the brain more efficiently will be conducted under an agreement signed between Nelson Research & Development Co. of Irvine and McLean Hospital Corp. of Boston.
Nelson officials declined to disclose the value of the agreement except to say that it will be "a major research program" scheduled to last about three years. Dr. Victor E. Shashoua, an associate professor of biological chemistry, psychiatry and neuroscience at Harvard Medical School, will oversee the research program.
Under the agreement, Nelson Research, with headquarters on the UC Irvine campus, will provide financing for the research in exchange for the first right to patent whatever Shashoua's research team discovers. A major factor in the company's decision to support the work was the encouraging preliminary work done by Shashoua.
"We are pleased to reach this agreement with such an innovative researcher," said Dr. Eric Nelson, chairman and president of Nelson Research, in a statement. "This research program is consistent with our basic work on receptors and novel drug delivery systems and has excellent potential for the development of methods for targeting drug delivery to any specific part of the body."